EUCTR2010-024431-17-IT进行中（未招募）不适用
A PILOT STUDY TO EVALUATE THE INCIDENCE OF HYPONATREMIA IN A MEDICAL-SURGICAL HOSPITAL AND TO EXPLORE THE EFFICACY AND SAFETY OF TOLVAPTAN IN THE CLINICAL PRACTICE - Tolvaptan for in-hospital hyponatremia
IST. DI RICERCHE FARMACOLOG. M. NEGRI0 个研究点开始时间: 2011年12月28日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Non artifactual hyponatremia in euvolemic or hypervolemic states, defined as serum sodium <135 mEq/L confirmed in at least 2 consecutive evaluations; - 18 years of age or older; - Able to give written Informed Consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Women who are breast feeding and females of childbearing potential who are not using acceptable contraceptive methods; - Hyponatremia in hypovolemic states; - Acute and transient hyponatremia associated with head trauma or post-operative state; - Hyponatremia due to uncontrolled hypothyroidism or uncontrolled adrenal insufficiency; - Cardiac surgery within 30 days prior to the potential study enrollment, excluding percutaneous coronary interventions; - History of a myocardial infarction within 30 days prior to the potential study enrollment; - History of sustained ventricular tachycardia or ventricular fibrillation within the last 30 days, unless in the presence of an automatic implantable cardioverter defibrillator; - Severe angina including angina at rest or at slight exertion and/or unstable angina; - History of a cerebrovascular accident within the last 30 days; - Subjects with psychogenic polydipsia may not be included, however subjects with other psychiatric illness may be included; - Systolic arterial blood pressure <90 mmHg; - History of hypersensitivity and/or idiosyncratic reaction to benzazepine or benzazepine derivatives (such as benazepril); - History of drug or medication abuse within the past year, or current alcohol abuse; - Uncontrolled diabetes mellitus defined as fasting glucose >300mg/dL; - Urinary tract obstruction except BPH if non-obstructive; - Terminally ill or moribund condition with little chance of short-term survival; - Serum creatinine >3.5 mg/dL; - Serum sodium <120 mEq/L with associated neurologic impairment, i.e. symptoms such as apathy, confusion, seizures; - Patients with progressive or episodic neurologic disease such as multiple sclerosis or history of multiple strokes; - Child-Pugh score greater than 10 (unless approved); - Patients receiving intravenous fluids at a rate greater than KVO (Keep Vein Open); - Hyponatremia due to lab artifacts; - Patients receiving AVP or its analogs for treatment of any condition; - Patients receiving within 7 days of randomization, other medications for treatment of hyponatremia specifically: demeclocycline, lithium carbonate or urea; - Patients likely requiring IV saline for correction of symptomatic or asymptomatic severe hyponatremia during the course of the study; - Severe pulmonary artery hypertension; - Hyponatremia should not be the result of any medication that can safely be withdrawn.
研究者
相似试验
已完成
不适用
Study about deficiency of thyroid hormones following removal of larynx in laryngeal cancersCTRI/2018/12/016652DR Architha Menon P42
招募中
2 期
A study to find out the effectiveness of oral temozolomide along with radiation in patients with grade IV glial tumors using a short course of Intensity modulated RadiotherapyCTRI/2021/01/030334Christian Medical College Vellore
招募中
2 期
IMPACT OF SWALLOWING THERAPY IN MANAGEMENT OF DYSPHAGIA POST RADIOTHERAPYCTRI/2020/04/024828PGIMER CHANDIGARH
进行中（未招募）
不适用
PILOT STUDY FOR THE EVALUATION OF THE EFFECTS OF INSULIN TREATMENT ON MYOCARDIAL FUNCTION, PERFUSION, AND GLUCOSE METABOLISM IN PATIENTS WITH PRIMARY LEFT VENTRICULAR DYSFUNCTION AND TYPE 2 DIABETESEUCTR2004-002729-34-ITAVENTIS PHARMA S.P.A.
进行中（未招募）
1 期
A PILOT STUDY TO EVALUATE THE EFFECT OF TRIGGERING FINAL OOCYTE MATURATION WITH GnRHa OR hCG ON ENDOMETRIAL RECEPTIVITY PARAMETERS AND THE LUTEAL PHASE IN OOCYTE DONORS - GnRHa vs hCG: impact on endometrial receptivityCompare the endometrium of oocyte donors, who had final oocyte maturation with either hCG, Suprefact, followed by hCG 35 hours after triggering, Suprefact or Suprefact without luteal phase support.Group A, B, C receive luteal phase support for 5 days, until the day of endometrial sampling (OPU+5).To avoid inter-patient variation in endometrial histology, each patient will preferably perform 4 consecutive oocyte donation cycles, within one year, using models A-D for final oocyte maturationEUCTR2009-009429-26-BEFREE UNIVERSITY OF BRUSSELS